Research ExplorerPublicationsElevated IgG4 in patient circulation is associated with the ...

Elevated IgG4 in patient circulation is associated with the risk of disease progression in melanoma

Standard

Elevated IgG4 in patient circulation is associated with the risk of disease progression in melanoma. / Karagiannis, Panagiotis; Villanova, Federica; Josephs, Debra H; Correa, Isabel; Van Hemelrijck, Mieke; Hobbs, Carl; Saul, Louise; Egbuniwe, Isioma U; Tosi, Isabella; Ilieva, Kristina M; Kent, Emma; Calonje, Eduardo; Harries, Mark; Fentiman, Ian; Taylor-Papadimitriou, Joyce; Burchell, Joy; Spicer, James F; Lacy, Katie E; Nestle, Frank O; Karagiannis, Sophia N.

In: ONCOIMMUNOLOGY, Vol. 4, No. 11, 11.2015, p. e1032492.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Karagiannis, P, Villanova, F, Josephs, DH, Correa, I, Van Hemelrijck, M, Hobbs, C, Saul, L, Egbuniwe, IU, Tosi, I, Ilieva, KM, Kent, E, Calonje, E, Harries, M, Fentiman, I, Taylor-Papadimitriou, J, Burchell, J, Spicer, JF, Lacy, KE, Nestle, FO & Karagiannis, SN 2015, 'Elevated IgG4 in patient circulation is associated with the risk of disease progression in melanoma', ONCOIMMUNOLOGY, vol. 4, no. 11, pp. e1032492. https://doi.org/10.1080/2162402X.2015.1032492

APA

Karagiannis, P., Villanova, F., Josephs, D. H., Correa, I., Van Hemelrijck, M., Hobbs, C., Saul, L., Egbuniwe, I. U., Tosi, I., Ilieva, K. M., Kent, E., Calonje, E., Harries, M., Fentiman, I., Taylor-Papadimitriou, J., Burchell, J., Spicer, J. F., Lacy, K. E., Nestle, F. O., & Karagiannis, S. N. (2015). Elevated IgG4 in patient circulation is associated with the risk of disease progression in melanoma. ONCOIMMUNOLOGY, 4(11), e1032492. https://doi.org/10.1080/2162402X.2015.1032492

Vancouver

Karagiannis P, Villanova F, Josephs DH, Correa I, Van Hemelrijck M, Hobbs C et al. Elevated IgG4 in patient circulation is associated with the risk of disease progression in melanoma. ONCOIMMUNOLOGY. 2015 Nov;4(11):e1032492. https://doi.org/10.1080/2162402X.2015.1032492

Bibtex

@article{7f38baba2a4a4932a03f02024aae3a0f,
title = "Elevated IgG4 in patient circulation is associated with the risk of disease progression in melanoma",
abstract = "Emerging evidence suggests pathological and immunoregulatory functions for IgG4 antibodies and IgG4(+) B cells in inflammatory diseases and malignancies. We previously reported that IgG4 antibodies restrict activation of immune effector cell functions and impair humoral responses in melanoma. Here, we investigate IgG4 as a predictor of risk for disease progression in a study of human sera (n = 271: 167 melanoma patients; 104 healthy volunteers) and peripheral blood B cells (n = 71: 47 melanoma patients; 24 healthy volunteers). IgG4 (IgG4/IgGtotal) serum levels were elevated in melanoma. High relative IgG4 levels negatively correlated with progression-free survival (PFS) and overall survival. In early stage (I-II) disease, serum IgG4 was independently negatively prognostic for progression-free survival, as was elevation of IgG4(+) circulating B cells (CD45(+)CD22(+)CD19(+)CD3(-)CD14(-)). In human tissues (n = 256; 108 cutaneous melanomas; 56 involved lymph nodes; 60 distant metastases; 32 normal skin samples) IgG4(+) cell infiltrates were found in 42.6% of melanomas, 21.4% of involved lymph nodes and 30% of metastases, suggesting inflammatory conditions that favor IgG4 at the peripheral and local levels. Consistent with emerging evidence for an immunosuppressive role for IgG4, these findings indicate association of elevated IgG4 with disease progression and less favorable clinical outcomes. Characterizing immunoglobulin and other humoral immune profiles in melanoma might identify valuable prognostic tools for patient stratification and in the future lead to more effective treatments less prone to tumor-induced blockade mechanisms.",
author = "Panagiotis Karagiannis and Federica Villanova and Josephs, {Debra H} and Isabel Correa and {Van Hemelrijck}, Mieke and Carl Hobbs and Louise Saul and Egbuniwe, {Isioma U} and Isabella Tosi and Ilieva, {Kristina M} and Emma Kent and Eduardo Calonje and Mark Harries and Ian Fentiman and Joyce Taylor-Papadimitriou and Joy Burchell and Spicer, {James F} and Lacy, {Katie E} and Nestle, {Frank O} and Karagiannis, {Sophia N}",
year = "2015",
month = nov,
doi = "10.1080/2162402X.2015.1032492",
language = "English",
volume = "4",
pages = "e1032492",
journal = "ONCOIMMUNOLOGY",
issn = "2162-402X",
publisher = "Taylor & Francis",
number = "11",

}

RIS

TY - JOUR

T1 - Elevated IgG4 in patient circulation is associated with the risk of disease progression in melanoma

AU - Karagiannis, Panagiotis

AU - Villanova, Federica

AU - Josephs, Debra H

AU - Correa, Isabel

AU - Van Hemelrijck, Mieke

AU - Hobbs, Carl

AU - Saul, Louise

AU - Egbuniwe, Isioma U

AU - Tosi, Isabella

AU - Ilieva, Kristina M

AU - Kent, Emma

AU - Calonje, Eduardo

AU - Harries, Mark

AU - Fentiman, Ian

AU - Taylor-Papadimitriou, Joyce

AU - Burchell, Joy

AU - Spicer, James F

AU - Lacy, Katie E

AU - Nestle, Frank O

AU - Karagiannis, Sophia N

PY - 2015/11

Y1 - 2015/11

N2 - Emerging evidence suggests pathological and immunoregulatory functions for IgG4 antibodies and IgG4(+) B cells in inflammatory diseases and malignancies. We previously reported that IgG4 antibodies restrict activation of immune effector cell functions and impair humoral responses in melanoma. Here, we investigate IgG4 as a predictor of risk for disease progression in a study of human sera (n = 271: 167 melanoma patients; 104 healthy volunteers) and peripheral blood B cells (n = 71: 47 melanoma patients; 24 healthy volunteers). IgG4 (IgG4/IgGtotal) serum levels were elevated in melanoma. High relative IgG4 levels negatively correlated with progression-free survival (PFS) and overall survival. In early stage (I-II) disease, serum IgG4 was independently negatively prognostic for progression-free survival, as was elevation of IgG4(+) circulating B cells (CD45(+)CD22(+)CD19(+)CD3(-)CD14(-)). In human tissues (n = 256; 108 cutaneous melanomas; 56 involved lymph nodes; 60 distant metastases; 32 normal skin samples) IgG4(+) cell infiltrates were found in 42.6% of melanomas, 21.4% of involved lymph nodes and 30% of metastases, suggesting inflammatory conditions that favor IgG4 at the peripheral and local levels. Consistent with emerging evidence for an immunosuppressive role for IgG4, these findings indicate association of elevated IgG4 with disease progression and less favorable clinical outcomes. Characterizing immunoglobulin and other humoral immune profiles in melanoma might identify valuable prognostic tools for patient stratification and in the future lead to more effective treatments less prone to tumor-induced blockade mechanisms.

AB - Emerging evidence suggests pathological and immunoregulatory functions for IgG4 antibodies and IgG4(+) B cells in inflammatory diseases and malignancies. We previously reported that IgG4 antibodies restrict activation of immune effector cell functions and impair humoral responses in melanoma. Here, we investigate IgG4 as a predictor of risk for disease progression in a study of human sera (n = 271: 167 melanoma patients; 104 healthy volunteers) and peripheral blood B cells (n = 71: 47 melanoma patients; 24 healthy volunteers). IgG4 (IgG4/IgGtotal) serum levels were elevated in melanoma. High relative IgG4 levels negatively correlated with progression-free survival (PFS) and overall survival. In early stage (I-II) disease, serum IgG4 was independently negatively prognostic for progression-free survival, as was elevation of IgG4(+) circulating B cells (CD45(+)CD22(+)CD19(+)CD3(-)CD14(-)). In human tissues (n = 256; 108 cutaneous melanomas; 56 involved lymph nodes; 60 distant metastases; 32 normal skin samples) IgG4(+) cell infiltrates were found in 42.6% of melanomas, 21.4% of involved lymph nodes and 30% of metastases, suggesting inflammatory conditions that favor IgG4 at the peripheral and local levels. Consistent with emerging evidence for an immunosuppressive role for IgG4, these findings indicate association of elevated IgG4 with disease progression and less favorable clinical outcomes. Characterizing immunoglobulin and other humoral immune profiles in melanoma might identify valuable prognostic tools for patient stratification and in the future lead to more effective treatments less prone to tumor-induced blockade mechanisms.

U2 - 10.1080/2162402X.2015.1032492

DO - 10.1080/2162402X.2015.1032492

M3 - SCORING: Journal article

C2 - 26451312

VL - 4

SP - e1032492

JO - ONCOIMMUNOLOGY

JF - ONCOIMMUNOLOGY

SN - 2162-402X

IS - 11

ER -